Switching endothelin receptor medicines and risk in pulmonary arterial hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational cohort of adults with right-heart-catheterization–confirmed PAH who have changed therapy from ambrisentan to bosentan within the prior six months. Researchers will collect clinical data, risk scores, laboratory tests (including liver enzymes), and follow-up assessments between 3 and 6 months after the switch. The goal is to describe real-world effects of the medication change on risk stratification, functional status, and hepatic safety. Data are recorded at a single center (InCor - FMUSP, University of São Paulo) using routine clinical visits and chart review.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Confirmed diagnosis of pulmonary arterial hypertension (PAH) by right heart catheterization
* Documented therapeutic switch from ambrisentan (10 mg once daily) to bosentan (125 mg twice daily) within the previous 6 months for the switch group
* Treatment with ambrisentan for at least 6 months without switching to bosentan for the maintenance group

Exclusion Criteria:

* History of severe hepatic impairment
* Incomplete clinical or laboratory records that prevent risk score calculation
* Inability to attend clinical follow-up between 3 and 6 months after medication switch

Where it's running

• InCor - FMUSP
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Study coordinator: Caio Fernandes, Principal Investigator
• Email: caio.cesar@hc.fm.usp.br
• Phone: PhD

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Timing of pulmonary arterial hypertension diagnosis in Brazil

  We will see how long it takes adults with pulmonary arterial hypertension in Brazil to get a confirmed diagnosis and what causes delays.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT06998329

• Improving adherence to PAH treatment with telemedicine and patient guidance

  This study will try whether regular telemedicine check-ins and guided education help people with PAH stick to their oral medications and manage side effects.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT06850792

• Rutgers Genetics of Pulmonary Hypertension

  This online project will try to see if genetic differences affect the risk of pulmonary hypertension in U.S. adults, and anyone 18 or older can join whether or not they have PH.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07217522

• Testing a patient questionnaire about pulmonary hypertension knowledge

  This project will test a questionnaire to measure what adults with pulmonary arterial hypertension know about their condition, treatments, and self-care.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07120789

• Sotatercept to support right ventricular function in pulmonary arterial hypertension

  This research will try sotatercept injections in adults with PAH to see if the medicine helps the right side of the heart work better.

  Recruiting Phase 4 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06658522

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.